Skip to content
DataLookout
Menu

NCT05260385

To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

StatusUnknown
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary completion date: Apr 30, 2024 to Oct 30, 2025
    • Study completion date: Apr 30, 2025 to Dec 30, 2025
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Eligibility criteria shortened, about 96 words
    • Primary endpoints: 2 to 1
    • Start date changed from estimate of Apr 30, 2022 to Jan 24, 2022
    • Interventions: KC1036 (Drug), KC1036 (Drug) to KC1036 (Drug)
    • Secondary endpoints: 7 to 8
    • Study description revised
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: approximately 2 year.

Secondary (8)

Progression-free survival (PFS)
Disease Control Rate (DCR)
Duration of Response (DOR)
Pharmacokinetics (PK) profile: Cmax
Pharmacokinetics (PK) profile: Tmax
Show 3 moreShow less
Pharmacokinetics (PK) profile: T1/2
Pharmacokinetics (PK) profile: AUC
Adverse events (AEs)

Arms and interventions

QD regimenExperimental

KC1036 was administered orally in 60 mg once daily, 21 days as a cycle.

BID regimenExperimental

Dose-Escalation part : KC1036 was administered orally in 20 mg BID, 30 mg BID, or 40 mg BID. Dose-Expansion part : According to the results of Dose-Escalation, an appropriate BID regimen was selected for Dose-Expansion .

Drugs: KC1036

Sites

13 sites in 1 country